4 recruiting. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 4 |
| Phase 1 | 2 | Recruiting 2 |
Follow NHL: new trials by email Literature Review of NHL trials Research Report on NHL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma CMOP±R - NHL | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 197 | 2024-07-08 | 2026-09-09 |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers IDP-023, Rituximab, Daratumumab - NHL, Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Indapta Therapeutics, INC. | 128 | 2023-10-25 | 2025-06-03 |
| Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients IM19 CAR-T Cells - NHL | Phase 1 / Phase 2 | Recruiting | Beijing Immunochina Medical Science & Technology Co., Ltd. | 52 | 2020-06-04 | 2020-12-08 |
| Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma DA-EPOCH, Rituximab, CHOP - Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 132 | 2019-08-05 | 2026-10-26 |
Lymphoma, Non-Hodgkin (2) · Hematologic Neoplasms (1) · Lymphoma, Large B-Cell, Diffuse (1) · Multiple Myeloma (1)
Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Hematologic Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Lymphoma, B-Cell (1) · Neoplasms by Site (1)
Cyclophosphamide (2) · Rituximab (2) · fludarabine (2) · EPOCH protocol (1) · Interleukin-2 (1) · Mesna (1) · acalabrutinib (1) · aldesleukin (1) · daratumumab (1) · isatuximab (1)
Beijing Immunochina Medical Science & Technology Co., Ltd. (1) · Indapta Therapeutics, INC. (1) · National Cancer Institute (NCI) (1) · The First Affiliated Hospital of Soochow University (1)
China (2) · United States (2)
Christopher J Melani, M.D. (1) · Haiwen Huang (1) · Yuqin Song, MD, PhD (1)